Patents by Inventor Irene Kuhn

Irene Kuhn has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Chimeric adenoviruses for use in cancer treatment
    Patent number: 9234185
    Abstract: The present invention relates to oncolytic adenoviruses having therapeutic applications. Recombinant chimeric adenoviruses, and methods to produce them are provided. The chimeric adenoviruses of the invention comprise nucleic acid sequences derived from adenoviral serotypes classified within the subgroups B through F and demonstrate an enhanced therapeutic index.
    Type: Grant
    Filed: August 20, 2014
    Date of Patent: January 12, 2016
    Assignee: PSIOXUS THERAPEUTICS LIMITED
    Inventors: Paul Harden, Terry Hermiston, Irene Kuhn
  • Chimeric adenoviruses for use in cancer treatment
    Patent number: 9115337
    Abstract: The present invention relates to oncolytic adenoviruses having therapeutic applications. Recombinant chimeric adenoviruses, and methods to produce them are provided. The chimeric adenoviruses of the invention comprise nucleic acid sequences derived from adenoviral serotypes classified within the subgroups B through F and demonstrate an enhanced therapeutic index.
    Type: Grant
    Filed: March 13, 2013
    Date of Patent: August 25, 2015
    Assignee: PsiOxus Therapeutics Limited
    Inventors: Paul Harden, Terry Hermiston, Irene Kuhn
  • Chimeric adenoviruses for use in cancer treatment
    Patent number: 9034344
    Abstract: The present invention relates to oncolytic adenoviruses having therapeutic applications. Recombinant chimeric adenoviruses, and methods to produce them are provided. The chimeric adenoviruses of the invention comprise nucleic acid sequences derived from adenoviral serotypes classified within the subgroups B through F and demonstrate an enhanced therapeutic index.
    Type: Grant
    Filed: April 15, 2013
    Date of Patent: May 19, 2015
    Assignee: PsiOxus Therapeutics Limited
    Inventors: Paul Harden, Terry Hermiston, Irene Kuhn
  • CHIMERIC ADENOVIRUSES FOR USE IN CANCER TREATMENT
    Publication number: 20150037874
    Abstract: The present invention relates to oncolytic adenoviruses having therapeutic applications. Recombinant chimeric adenoviruses, and methods to produce them are provided. The chimeric adenoviruses of the invention comprise nucleic acid sequences derived from adenoviral serotypes classified within the subgroups B through F and demonstrate an enhanced therapeutic index.
    Type: Application
    Filed: August 20, 2014
    Publication date: February 5, 2015
    Inventors: Paul HARDEN, Terry HERMISTON, Irene KUHN
  • Chimeric adenoviruses for use in cancer treatment
    Patent number: 8765463
    Abstract: The present invention relates to oncolytic adenoviruses having therapeutic applications. Recombinant chimeric adenoviruses, and methods to produce them are provided. The chimeric adenoviruses of the invention comprise nucleic acid sequences derived from adenoviral serotypes classified within the subgroups B through F and demonstrate an enhanced therapeutic index.
    Type: Grant
    Filed: April 10, 2012
    Date of Patent: July 1, 2014
    Assignee: PsiOxus Therapeutics Limited
    Inventors: Paul Harden, Terry Hermiston, Irene Kuhn
  • CHIMERIC ADENOVIRUSES FOR USE IN CANCER TREATMENT
    Publication number: 20130230902
    Abstract: The present invention relates to oncolytic adenoviruses having therapeutic applications. Recombinant chimeric adenoviruses, and methods to produce them are provided. The chimeric adenoviruses of the invention comprise nucleic acid sequences derived from adenoviral serotypes classified within the subgroups B through F and demonstrate an enhanced therapeutic index.
    Type: Application
    Filed: April 10, 2012
    Publication date: September 5, 2013
    Applicant: PsiOxus Therapeutics Limited
    Inventors: Paul HARDEN, Terry HERMISTON, Irene KUHN
  • CHIMERIC ADENOVIRUSES FOR USE IN CANCER TREATMENT
    Publication number: 20130217095
    Abstract: The present invention relates to oncolytic adenoviruses having therapeutic applications. Recombinant chimeric adenoviruses, and methods to produce them are provided. The chimeric adenoviruses of the invention comprise nucleic acid sequences derived from adenoviral serotypes classified within the subgroups B through F and demonstrate an enhanced therapeutic index.
    Type: Application
    Filed: April 15, 2013
    Publication date: August 22, 2013
    Applicant: PSIOXUS THERAPEUTICS LIMITED
    Inventors: Paul HARDEN, Terry HERMISTON, Irene KUHN
  • CHIMERIC ADENOVIRUSES FOR USE IN CANCER TREATMENT
    Publication number: 20130209409
    Abstract: The present invention relates to oncolytic adenoviruses having therapeutic applications. Recombinant chimeric adenoviruses, and methods to produce them are provided. The chimeric adenoviruses of the invention comprise nucleic acid sequences derived from adenoviral serotypes classified within the subgroups B through F and demonstrate an enhanced therapeutic index.
    Type: Application
    Filed: March 13, 2013
    Publication date: August 15, 2013
    Inventors: Paul Harden, Terry Hermiston, Irene Kuhn
  • CHIMERIC ADENOVIRUSES FOR USE IN CANCER TREATMENT
    Publication number: 20120231524
    Abstract: The present invention relates to oncolytic adenoviruses having therapeutic applications. Recombinant chimeric adenoviruses, and methods to produce them are provided. The chimeric adenoviruses of the invention comprise nucleic acid sequences derived from adenoviral serotypes classified within the subgroups B through F and demonstrate an enhanced therapeutic index.
    Type: Application
    Filed: April 10, 2012
    Publication date: September 13, 2012
    Applicant: PsiOxus Therapeutics Limited
    Inventors: Paul HARDEN, Terry HERMISTON, Irene KUHN
  • Generation of oncolytic adenoviruses and uses thereof
    Patent number: 8216819
    Abstract: The present invention relates to a method for the production of onolytic adenoviruses having increased potency and their therapeutic applications for cancer. Recombinant adenoviruses and methods to produce them are provided.
    Type: Grant
    Filed: December 20, 2007
    Date of Patent: July 10, 2012
    Assignee: PsiOxus Therapeutics Limited
    Inventors: Terry Hermiston, Irene Kuhn
  • Chimeric adenoviruses for use in cancer treatment
    Patent number: 8158599
    Abstract: The present invention relates to oncolytic adenoviruses having therapeutic applications. Recombinant chimeric adenoviruses, and methods to produce them are provided. The chimeric adenoviruses of the invention comprise nucleic acid sequences derived from adenoviral serotypes classified within the subgroups B through F and demonstrate an enhanced therapeutic index.
    Type: Grant
    Filed: March 30, 2009
    Date of Patent: April 17, 2012
    Assignee: PsiOxus Therapeutics Limited
    Inventors: Paul Harden, Terry Hermiston, Irene Kuhn
  • GENERATION OF ONCOLYTIC ADENOVIRUSES AND USES THEREOF
    Publication number: 20100136658
    Abstract: The present invention relates to a method for the production of onolytic adenoviruses having increased potency and their therapeutic applications for cancer. Recombinant adenoviruses and methods to produce them are provided.
    Type: Application
    Filed: December 20, 2007
    Publication date: June 3, 2010
    Applicant: BAYER SCHERING PHARMA AG
    Inventors: Terry Hermiston, Irene KUHN
  • CHIMERIC ADENOVIRUSES FOR USE IN CANCER TREATMENT
    Publication number: 20090227000
    Abstract: The present invention relates to oncolytic adenoviruses having therapeutic applications. Recombinant chimeric adenoviruses, and methods to produce them are provided. The chimeric adenoviruses of the invention comprise nucleic acid sequences derived from adenoviral serotypes classified within the subgroups B through F and demonstrate an enhanced therapeutic index.
    Type: Application
    Filed: March 30, 2009
    Publication date: September 10, 2009
    Applicant: BAYER SCHERING PHARMA AG
    Inventors: Paul HARDEN, Terry HERMISTON, Irene KUHN
  • Chimeric adenoviruses for use in cancer treatment
    Patent number: 7510868
    Abstract: The present invention relates to oncolytic adenoviruses having therapeutic applications. Recombinant chimeric adenoviruses, and methods to produce them are provided. The chimeric adenoviruses of the invention comprise nucleic acid sequences derived from adenoviral serotypes classified within the subgroups B through F and demonstrate an enhanced therapeutic index.
    Type: Grant
    Filed: May 24, 2005
    Date of Patent: March 31, 2009
    Inventors: Paul Harden, Terry Hermiston, Irene Kuhn
  • Chimeric adenoviruses for use in cancer treatment
    Publication number: 20050265973
    Abstract: The present invention relates to oncolytic adenoviruses having therapeutic applications. Recombinant chimeric adenoviruses, and methods to produce them are provided. The chimeric adenoviruses of the invention comprise nucleic acid sequences derived from adenoviral serotypes classified within the subgroups B through F and demonstrate an enhanced therapeutic index.
    Type: Application
    Filed: May 24, 2005
    Publication date: December 1, 2005
    Applicant: Schering Aktiengesellschaft
    Inventors: Paul Harden, Terry Hermiston, Irene Kuhn
  • DNA encoding an antigenic protein derived from Eimeria tenella and vaccines for prevention of coccidiosis caused by Eimeria tenella
    Patent number: 5187080
    Abstract: Nucleic acid molecules are provided which encode antigenic proteins capable of inducing in a chicken an immune response conferring protection against Eimeria tenella. Expression vectors containing the nucleic acid molecules are also provided. Methods for producing the proteins or antigenic polypeptides having amino acid sequences included within these proteins are also provided.
    Type: Grant
    Filed: January 21, 1992
    Date of Patent: February 16, 1993
    Assignee: Solvay & Cie S.A.
    Inventors: William H. Andrews, Virginia M. Brothers, James G. Files, Irene Kuhn, Michael T. McCaman, Stacey R. Sias, Leland S. Paul, Thomas C. Gore, Karel Z. Newman, Jr., John L. Tedesco
  • DNA encoding an antigenic protein derived from Eimeria tenella and vaccines for prevention of coccidiosis caused by Eimeria tenella
    Patent number: 4874705
    Abstract: A genomic DNA molecule having the nucleic acid sequence set forth in FIG. 1 and encoding an antigenic protein derived from Eimeria tenella has been isolated. The protein has a molecular weight of about 25,000 daltons and is composed of two polypeptides joined by a disulfide bond. One of the polypeptides is characterized by a molecular weight of about 17,000 daltons and by a blocked N-terminal amino acid and having the amino acid sequence set forth in FIG. 1. The other polypeptide is characterized by a molecular weight of about 8,000 daltons and has the amino acid sequence set forth in FIG. 1.A cDNA molecule encoding the 25,000 dalton polypeptide with a continuous amino acid sequence has been inserted into expression vectors capable of expressing the 25,000 dalton polypeptide directly or as a fused polypeptide. The polypeptides produced are used in vaccines to immunize chickens against infection by Eimeria tenella.
    Type: Grant
    Filed: December 6, 1985
    Date of Patent: October 17, 1989
    Assignee: Solvay & Cie, S.A.
    Inventors: William H. Andrews, Virginia M. Brothers, James G. Files, Irene Kuhn, Michael T. McCaman, Leland S. Paul, Stacey R. Sias, Thomas C. Gore, Karel Z. Newman, Jr., John L. Tedesco